Literature DB >> 1620344

Borrelia burgdorferi and other related spirochetes bind to galactocerebroside.

J C Garcia Monco1, B Fernandez Villar, R C Rogers, A Szczepanski, C M Wheeler, J L Benach.   

Abstract

Spirochetes are agents of neurologic disease that may utilize specific neural cell surface molecules for adhesion. Borrelia burgdorferi, the etiologic agent of Lyme disease, bound to galactocerebroside (GalCer) in numbers that were two- to threefold greater than to ceramide and glucocerebroside, and four- to fivefold greater than to sphingosine, psychosine, sulfatide, cholesterol, and three membrane phospholipids. The adherence was greater to GalCer and ceramide with a higher content of alpha-hydroxyl fatty acids. Treponema phagedenis Reiter and Borrelia hermsii also bound to GalCer. The binding of B burgdorferi to GalCer was inhibited in a concentration-dependent manner by rabbit polyclonal and murine monoclonal antibodies to this glycosphingolipid component of myelin. The monoclonal antibody to GalCer also inhibited adhesion of the organisms to Schwann cells. Neither free D or L monosaccharides nor the lectin peanut agglutinin inhibited binding. Since B burgdorferi and other spirochetes cause neurologic disease, these results suggest a role for GalCer as a binding site in both the central and peripheral nervous systems.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1620344     DOI: 10.1212/wnl.42.7.1341

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

Review 1.  Host-pathogen interactions in the immunopathogenesis of Lyme disease.

Authors:  L T Hu; M S Klempner
Journal:  J Clin Immunol       Date:  1997-09       Impact factor: 8.317

2.  Interaction of a neurotropic strain of Borrelia turicatae with the cerebral microcirculation system.

Authors:  Nilay Sethi; Marie Sondey; Yunhong Bai; Kwang S Kim; Diego Cadavid
Journal:  Infect Immun       Date:  2006-08-28       Impact factor: 3.441

3.  Specificities and sensitivities of four monoclonal antibodies for typing of Borrelia burgdorferi sensu lato isolates.

Authors:  A G Bretz; K Ryffel; P Hutter; E Dayer; O Péter
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

4.  Different classes of proteoglycans contribute to the attachment of Borrelia burgdorferi to cultured endothelial and brain cells.

Authors:  J M Leong; H Wang; L Magoun; J A Field; P E Morrissey; D Robbins; J B Tatro; J Coburn; N Parveen
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

5.  Structural requirements for glycosaminoglycan recognition by the Lyme disease spirochete, Borrelia burgdorferi.

Authors:  J M Leong; D Robbins; L Rosenfeld; B Lahiri; N Parveen
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

6.  Interaction of variable bacterial outer membrane lipoproteins with brain endothelium.

Authors:  Gaurav Gandhi; Diana Londoño; Christine R Whetstine; Nilay Sethi; Kwang S Kim; Wolfram R Zückert; Diego Cadavid
Journal:  PLoS One       Date:  2010-10-22       Impact factor: 3.240

7.  Experimental immunization with Borrelia burgdorferi induces development of antibodies to gangliosides.

Authors:  J C Garcia-Monco; R J Seidman; J L Benach
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

8.  The plasminogen activation system enhances brain and heart invasion in murine relapsing fever borreliosis.

Authors:  J A Gebbia; J C Monco; J L Degen; T H Bugge; J L Benach
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

Review 9.  The pathogenesis of lyme neuroborreliosis: from infection to inflammation.

Authors:  Tobias A Rupprecht; Uwe Koedel; Volker Fingerle; Hans-Walter Pfister
Journal:  Mol Med       Date:  2008 Mar-Apr       Impact factor: 6.354

10.  Possible role of glial cells in the onset and progression of Lyme neuroborreliosis.

Authors:  Geeta Ramesh; Juan T Borda; Amy Gill; Erin P Ribka; Lisa A Morici; Peter Mottram; Dale S Martin; Mary B Jacobs; Peter J Didier; Mario T Philipp
Journal:  J Neuroinflammation       Date:  2009-08-25       Impact factor: 9.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.